Tenaya Therapeutics (NASDAQ:TNYA) Posts Earnings Results, Hits Estimates

Key Points

• Tenaya reported EPS of ($0.09) which matched estimates, but revenue was only $0.23 million versus a consensus $7.50 million, representing a significant revenue miss.
• Major shareholder Group GP LP Column III sold 3,511,826 shares at about $0.56 (part of 8,594,047 insider shares sold worth $5.43M over the last three months), indicating notable insider selling.
• TNYA traded around $0.79 (market cap ≈ $171M) with a 12‑month range of $0.36–$2.35, and analysts' consensus is a Moderate Buy with an average target price of $4.00.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.09), FiscalAI reports. The firm had revenue of $0.23 million for the quarter, compared to the consensus estimate of $7.50 million.

Tenaya Therapeutics Stock Performance

TNYA stock traded up $0.04 during trading on Wednesday, reaching $0.79. 4,838,859 shares of the company traded hands, compared to its average volume of 4,088,382. Tenaya Therapeutics has a 12 month low of $0.36 and a 12 month high of $2.35. The business has a 50 day simple moving average of $0.72 and a 200 day simple moving average of $0.93. The company has a market capitalization of $171.47 million, a price-to-earnings ratio of -1.27 and a beta of 2.77.

Insider Buying and Selling

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III sold 3,511,826 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $0.56, for a total value of $1,966,622.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 8,594,047 shares of company stock valued at $5,430,207 in the last three months. Company insiders own 48.65% of the company's stock.

Institutional Trading of Tenaya Therapeutics

A number of institutional investors have recently bought and sold shares of TNYA. Scientech Research LLC acquired a new stake in Tenaya Therapeutics in the 3rd quarter worth approximately $27,000. Geode Capital Management LLC boosted its stake in Tenaya Therapeutics by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 1,193,355 shares of the company's stock worth $849,000 after purchasing an additional 17,820 shares in the last quarter. Cetera Investment Advisers boosted its stake in Tenaya Therapeutics by 107.0% in the 4th quarter. Cetera Investment Advisers now owns 106,425 shares of the company's stock worth $76,000 after purchasing an additional 55,000 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in Tenaya Therapeutics in the 3rd quarter worth approximately $99,000. Finally, Comerica Bank acquired a new stake in Tenaya Therapeutics in the 1st quarter worth approximately $50,000. 90.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Chardan Capital reissued a "buy" rating and set a $8.00 price target on shares of Tenaya Therapeutics in a research report on Thursday, March 12th. Wall Street Zen downgraded Tenaya Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 14th. Leerink Partners reaffirmed an "outperform" rating and set a $2.00 price objective on shares of Tenaya Therapeutics in a research report on Thursday, March 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tenaya Therapeutics in a research report on Wednesday, January 21st. Finally, Lifesci Capital raised Tenaya Therapeutics to a "strong-buy" rating in a research report on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $4.00.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.